Related Experiment Video
Updated: Jan 19, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Association between dyslipidemia and CCL2 in patients undergoing hemodialysis
Wander Valadares de Oliveira Junior1, Ana Paula Ferreira Silva1, Roberta Carvalho de Figueiredo1
1Campus Centro Oeste-Universidade Federal de São João Del-Rei, Brazil.
Insights
C-C Motif Chemokine Ligand 2 (CCL2) plasma levels are linked to dyslipidemia in hemodialysis patients. This finding suggests CCL2 may play a role in cardiovascular disease development for these individuals.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Immunology
Background:
- Hemodialysis (HD) patients face elevated cardiovascular disease (CVD) risks, including heart attack, stroke, and heart failure.
- C-C Motif Chemokine Ligand 2 (CCL2), also known as monocyte chemotactic protein-1 (MCP-1), is implicated in inflammatory processes and its levels increase in dyslipidemic chronic kidney disease (CKD) patients on HD.
Purpose of the Study:
- To investigate the association between plasma C-C Motif Chemokine Ligand 2 (CCL2) levels and dyslipidemia in patients undergoing hemodialysis (HD).
Main Methods:
- A cross-sectional study included 160 Brazilian HD patients.
- CCL2 plasma levels were quantified using capture ELISA.
- Linear regression analysis, adjusted for CVD risk factors, was employed to assess the association between CCL2 and dyslipidemia.
Main Results:
- A statistically significant association was found between CCL2 plasma levels and dyslipidemia (P=0.029).
- This association remained significant after adjusting for confounding variables like age, gender, BMI, diabetes, HD duration, and weight gain (P=0.045).
Conclusions:
- Elevated CCL2 levels are associated with dyslipidemia in HD patients, suggesting a potential role for this cytokine in the pathogenesis of cardiovascular complications.
- Further understanding of this mechanism could lead to novel therapeutic strategies to mitigate CVD in HD patients.
Introduction:
Hemodialysis (HD) is associated with high risk for cardiovascular diseases including acute myocardial infarction, stroke and congestive heart failure. C-C Motif Chemokine Ligand 2 (CCL2), also known monocyte chemotactic protein-1 (MCP-1) can be produced by a variety of cells, reaching increased levels in dyslipidemic chronic kidney disease (CKD) patients undergoing HD treatment. The main of this study was to evaluate the association between of CCL2 plasma levels and dyslipidemia in CKD patients undergoing HD.
Methods:
A cross-sectional study enrolled 160 Brazilian HD patients. CCL2 plasma levels were measured by capture ELISA. The association between CCL2 levels and dyslipidemia was investigated using linear regression, adjusted for classic and non-classical CVD risk factors.
Results:
A significant association was observed between CCL2 levels and dyslipidemia (P = 0.029), even after adjustment for possible confounding variables, such as age, gender, body mass index, diabetes mellitus, HD time, urea pre-hemodialysis and interdialytic weight gain (P = 0.045).
Conclusion:
Our findings show that CCL2 levels are associated with dyslipidemia, which suggests a role of this cytokine in the pathogenesis of cardiovascular disease in HD patients. A better understanding of this pathogenesis could contribute to the discovery of new therapeutic targets that would reduce cardiovascular complications in these patients.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Hemodialysis II: Procedure and Complications

